MBS314

MBS314 is a novel T-cell engager targeting GPRC5D, BCMA, and CD3, specifically for the treatment of multiple myeloma. The product is currently in the phase I/II clinical trial in China. The product is based on our multispecific antibody technology platform and has secured patents in mainland China, Taiwan, and Hong Kong, with plans for global patent expansion. The company has also established a strategic partnership with Pfizer to accelerate the overseas clinical development of MBS314. The Investigational New Drug (IND) application for MBS314 (SC) for Phase I clinical trial has been approved by the U.S. Food and Drug Administration (FDA), and it is intended for the treatment of relapsed/refractory multiple myeloma.

The incidence of multiple myeloma is increasing annually in China and globally. Currently, there are no trispecific antibodies targeting GPRC5D, BCMA, and CD3 approved for sale worldwide. MBS314 is in the Phase I/II clinical trial and is expected to provide a more effective treatment option for multiple myeloma patients.